Gene therapy for surfactant protein B deficiency using recombinant AAV

Gene therapy for surfactant protein B deficiency using recombinant AAV

Opis bibliograficzny
Główni autorzy:	Meyer-Berg, H, Hyde, S, Gill, D
Format:	Conference item
Wydane:	Elsevier 2019

Podobne zapisy

Gene therapy for surfactant protein B deficiency using recombinant AAV vectors
od: Meyer-Berg, H
Wydane: (2021)

A human surfactant B deficiency air-liquid interface cell culture model suitable for gene therapy applications
od: Munis, AM, i wsp.
Wydane: (2020)

Identification of AAV serotypes for lung gene therapy in human embryonic stem cell-derived lung organoids
od: Meyer-Berg, H, i wsp.
Wydane: (2020)

Identification of AAV serotypes for lung gene therapy in human embryonic stem cell-derived lung organoids
od: Helena Meyer-Berg, i wsp.
Wydane: (2020-10-01)

Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola
od: Tan, T, i wsp.
Wydane: (2017)

Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer.
od: William E Grose, i wsp.
Wydane: (2012-01-01)

Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques
od: Liam Cole, i wsp.
Wydane: (2021-04-01)

Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy
od: Yuji Kashiwakura, i wsp.
Wydane: (2023-09-01)

Single-Step Purification/Solubilization of Recombinant Proteins: Application to Surfactant Protein B
od: Andreas Holzinger, i wsp.
Wydane: (1996-05-01)

Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epstein–Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBV + lymphoproliferative disorders
od: Elham Ahmadi, i wsp.
Wydane: (2021-11-01)

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
od: Shin'ichi Takeda, i wsp.
Wydane: (2013-06-01)

An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases
od: Luo T, i wsp.
Wydane: (2022-06-01)

Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy
od: Reetta A. E. Eriksson, i wsp.
Wydane: (2022-12-01)

Immunogenicity and toxicity of AAV gene therapy
od: Hildegund C. J. Ertl
Wydane: (2022-08-01)

AAV gene therapy vectors in the TMJ
od: Sabine M. Brouxhon, i wsp.
Wydane: (2022-12-01)

Allometric-like scaling of AAV gene therapy for systemic protein delivery
od: Alexandra Burr, i wsp.
Wydane: (2022-12-01)

Establishment of mouse model of inherited PIGO deficiency and therapeutic potential of AAV-based gene therapy
od: Ryoko Kuwayama, i wsp.
Wydane: (2022-06-01)

Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys
od: Julien Baruteau, i wsp.
Wydane: (2021-12-01)

Assessment of toxicity and biodistribution of recombinant AAV8 vector–mediated immunomodulatory gene therapy in mice with Pompe disease
od: Gensheng Wang, i wsp.
Wydane: (2014-01-01)

Probing recombinant AAV capsid integrity and genome release after thermal stress by mass photometry
od: Eduard H.T.M. Ebberink, i wsp.
Wydane: (2024-09-01)

Variation in the surfactant protein B gene is associated with development of emphysema in alpha 1 anti-trypsin deficiency
od: Wood, A, i wsp.
Wydane: (2007)

Lentiviral gene therapy for the treatment of ABCA3-mediated surfactant deficiency
od: Ruffle, AR
Wydane: (2024)

Adding recombinant AAVs to the cancer therapeutics mix
od: Patrick L. Mulcrone, i wsp.
Wydane: (2022-12-01)

The Role of Recombinant AAV in Precise Genome Editing
od: Swati Bijlani, i wsp.
Wydane: (2022-01-01)

Gene Transfer in Rodent Nervous Tissue Following Hindlimb Intramuscular Delivery of Recombinant Adeno-Associated Virus Serotypes AAV2/6, AAV2/8, and AAV2/9
od: Asad Jan, i wsp.
Wydane: (2019-11-01)

Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy
od: Reetta A. E. Eriksson, i wsp.
Wydane: (2023-03-01)

Corrigendum to âAssessment of toxicity and biodistribution of recombinant AAV8 vectorâmediated immunomodulatory gene therapy in mice with Pompe diseaseâ
od: Gensheng Wang, i wsp.
Wydane: (2015-01-01)

Editorial: Immunogenicity and toxicity of AAV gene therapy
od: Allison Bradbury, i wsp.
Wydane: (2023-06-01)

Difficulties in the treatment of an infant survivor with inherited surfactant protein-B deficiency in Tunisia
od: Samia Hamouda, i wsp.
Wydane: (2022-01-01)

Inclusion of PF68 surfactant improves stability of rAAV titer when passed through a surgical device used in retinal gene therapy
od: Patrício, M, i wsp.
Wydane: (2019)

Robust AAV Genotyping Based on Genetic Distances in Rep Gene That Are Maintained by Ubiquitous Recombination
od: Marina I. Beloukhova, i wsp.
Wydane: (2022-05-01)

AAV-based gene replacement: The promise of gene therapy for deafness
od: Jieyu Qi, i wsp.
Wydane: (2024-06-01)

Rational Design of AAV-rh74, AAV3B, and AAV8 with Limited Liver Targeting
od: Christopher Chan, i wsp.
Wydane: (2023-10-01)

Optimizing an AAV-CRISPR system for retinal gene therapy
od: Stevanovic, M
Wydane: (2019)

Choroideremia: molecular mechanisms and development of AAV gene therapy
od: Patrício, M, i wsp.
Wydane: (2018)

Progress of gene therapy based on AAV inhereditary deafness
od: Qi Jieyu, i wsp.
Wydane: (2021-06-01)

AAV for Gene Therapy in Ocular Diseases: Progress and Prospects
od: Xiaoyu He, i wsp.
Wydane: (2023-01-01)

AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy
od: Ridhwaanah Jacobs, i wsp.
Wydane: (2023-12-01)

Evaluation of AAV-DJ vector for retinal gene therapy
od: Yusaku Katada, i wsp.
Wydane: (2019-01-01)

Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy
od: Miranda Gehrke, i wsp.
Wydane: (2022-06-01)